237 related articles for article (PubMed ID: 12387694)
1. Use of the dopamine agonist cabergoline in the treatment of movement disorders.
Marco AD; Appiah-Kubi LS; Chaudhuri KR
Expert Opin Pharmacother; 2002 Oct; 3(10):1481-7. PubMed ID: 12387694
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Parkinson's disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist.
Porter MC; Appiah-Kubf LS; Chaudhuri KR
Int J Clin Pract; 2002; 56(6):468-74. PubMed ID: 12166546
[TBL] [Abstract][Full Text] [Related]
3. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
4. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
Linazasoro G;
Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
[TBL] [Abstract][Full Text] [Related]
5. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect.
Ahlskog JE; Wright KF; Muenter MD; Adler CH
Clin Neuropharmacol; 1996 Jun; 19(3):202-12. PubMed ID: 8726539
[TBL] [Abstract][Full Text] [Related]
6. Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients.
Del Dotto P; Colzi A; Pardini C; Lucetti C; Dubini A; Grimaldi R; Bonuccelli U
J Neural Transm Suppl; 1995; 45():259-65. PubMed ID: 8748633
[TBL] [Abstract][Full Text] [Related]
7. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD
Drugs; 1998; 55 Suppl 1():23-30. PubMed ID: 9483167
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology of dopamine agonists in Parkinson's disease.
Lange KW
Drugs Aging; 1998 Nov; 13(5):381-9. PubMed ID: 9829165
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa.
Marsden CD
Drugs; 1998; 55 Suppl 1():17-22. PubMed ID: 9483166
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of cabergoline and levodopa in Japanese patients with early Parkinson's disease: a 5-year prospective study.
Utsumi H;
Acta Med Okayama; 2012; 66(2):163-70. PubMed ID: 22525474
[TBL] [Abstract][Full Text] [Related]
11. Cabergoline for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KH
Cochrane Database Syst Rev; 2001; 2001(1):CD001518. PubMed ID: 11279720
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.
Fariello RG
Drugs; 1998; 55 Suppl 1():10-6. PubMed ID: 9483165
[TBL] [Abstract][Full Text] [Related]
13. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KD
Cochrane Database Syst Rev; 2001; 2001(1):CD001519. PubMed ID: 11279721
[TBL] [Abstract][Full Text] [Related]
14. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease.
Hutton JT; Koller WC; Ahlskog JE; Pahwa R; Hurtig HI; Stern MB; Hiner BC; Lieberman A; Pfeiffer RF; Rodnitzky RL; Waters CH; Muenter MD; Adler CH; Morris JL
Neurology; 1996 Apr; 46(4):1062-5. PubMed ID: 8780092
[TBL] [Abstract][Full Text] [Related]
15. Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys.
Bélanger N; Grégoire L; Hadj Tahar A; Bédard PJ
Mov Disord; 2003 Dec; 18(12):1436-41. PubMed ID: 14673879
[TBL] [Abstract][Full Text] [Related]
16. Cabergoline : a review of its use in the treatment of Parkinson's disease.
Curran MP; Perry CM
Drugs; 2004; 64(18):2125-41. PubMed ID: 15341508
[TBL] [Abstract][Full Text] [Related]
17. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
Inzelberg R; Schechtman E; Nisipeanu P
Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology of dopamine agonists.
Lam YW
Pharmacotherapy; 2000 Jan; 20(1 Pt 2):17S-25S. PubMed ID: 10641988
[TBL] [Abstract][Full Text] [Related]
19. New pharmacotherapy for Parkinson's disease.
Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
[TBL] [Abstract][Full Text] [Related]
20. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
Chase TN
Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
